The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Therapeutic efficacy of the combination of entecavir and thymosin alpha 1 on patients with HBeAg-positive chronic hepatitis B
Author(s): 
Pages: 235-236
Year: Issue:  4
Journal: INFECTIOUS DISEASE INFORMATION

Keyword:  肝炎乙型慢性乙型肝炎e抗原治疗结果;
Abstract: 目的 探讨恩替卡韦片联合胸腺肽α1 治疗HBeAg 阳性慢性乙型肝炎的疗效.方法 140 例慢性乙型肝炎患者随机分为2 组,治疗组(72 例)口服恩替卡韦片,0.5 mg/次,1 次/d,同时给予胸腺肽α1 皮下注射,1.6 mg/次,2 次/周;对照组(68例)单用恩替卡韦片口服,0.5 mg/次,1 次/d,2 组均连用48 周.结果 治疗组HBeAg 转阴率为58.33%,HBeAg/抗HBe 转换率为38.89%,明显高于对照组(23.53%、11.76%),差异有统计学意义(P 均<0.01).2 组HBV DNA 转阴率及ALT 复常率差异无统计学意义(P 均>0.05).结论 恩替卡韦片联合胸腺肽α1 治疗慢性乙型肝炎可提高HBeAg 转阴率和HBeAg/抗HBe 血清转换率.
Related Articles
No related articles found